Navigation Links
Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172
Date:8/14/2008

e (aPTT). The highest infusion dose rate tested, 6.0 mg/kg/hr, resulted in an average ACT per subject ranging from 373 to 414 seconds and an increase of approximately three times baseline. Average PT values per subject ranged from 56 to 92 seconds and had an increase of approximately five times baseline. Average aPTT values per subject ranged from 130 to 178 seconds and had an increase of approximately five times baseline. All measurements were maintained stably throughout the four-hour infusion. Once the infusion ended, the ACT and other coagulation parameters showed a rapid return toward baseline, consistent with the short plasma half-life of NU172 observed in the Phase 1a trial. In addition, NU172 was well-tolerated with no serious adverse events.

"In this study, we were able to identify a dose that meets or exceeds the level of anticoagulation needed for the indications we plan to evaluate, including CABG surgery," said Dr. Ted W. Love, chairman and chief executive officer of Nuvelo. "In addition to supporting our previous proof-of-concept data, the Phase 1b study shows that anticoagulation with NU172 can be maintained for four hours, which is longer than a typical CABG procedure. We are on track to launch a Phase 2 study evaluating NU172 in the fourth quarter of 2008 or the first quarter of 2009."

Approximately 450,000 CABG procedures, 50 million dialysis procedures, and 1.2 million PCIs are performed annually in the U.S. During these procedures, anticoagulants are given to prevent blood clotting. In CABG procedures and often in dialysis, the anticoagulation effect of heparin must be reversed with protamine once the procedure has been completed.

About Aptamers and NU172

Aptamers are chemically synthesized single-stranded nucleic acids that form well-defined three-dimensional shapes, allowing them to bind target molecules in a manner that is conceptually similar to antibodies. Characteristics of aptamers include high specificity and a
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
2. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
3. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
4. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
5. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
6. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
7. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. NewCardio Announces Positive Results From Third Clinical Validation Study
10. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
11. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  Acsis Inc., ... protection and serialization solutions, has recently posted an ... that addresses current and future needs for companies, ... the old supply chain model no longer work ... technology, including the growth of mobile technology, machine ...
(Date:7/25/2014)... , July 25, 2014 Research ... "Global Ophthalmic Diagnostic Devices Market 2014-2018" report ... About Ophthalmic Diagnostic Device ... used to identify a defect or deficiency in the ... with ophthalmic disorders such as presbyopia, cataracts, glaucoma, retinal ...
(Date:7/25/2014)... July 25, 2014 Leading events organizer ... returning for the seventh year to São Paulo, ... August 2014. The event will co-locate with Food Ingredients ... most comprehensive meeting point for the pharmaceutical industry. ... countries for pharmaceutical sales are now exploring the ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4
(Date:7/25/2014)... genes are switched on or off plays a key ... metabolism, UT Southwestern Medical Center researchers have found., The ... obesity and diabetes, since the transcription factor involved ... influence the body,s sensitivity to insulin and leptin signaling. ... regulation of food intake and sugar disposal, and obesity ...
(Date:7/25/2014)... Innerspire, LLC ( http://www.innerspire.com ) announced ... a Creative Enrollment Specialist. In this role, Greg will ... well as his accomplished design skills to further develop ... to service the creative marketing needs of ... with small business owners and individuals looking to accelerate ...
(Date:7/25/2014)... 2014 The American Brain Tumor Association ... “ABTA CommYOUnity™” during its annual patient and family conference ... the brain tumor community as we – the first ... support services and funding brain tumor research – extend ... brain tumor awareness and getting our materials and services ...
(Date:7/25/2014)... 25, 2014 There are 700,000 people in ... each day. Though when someone hears the words, “you have ... unsure of the next step and where to turn. , ... out that next step by providing and pursuing the answers ... Brian Olson, member of the ABTA’s Board of Directors and ...
(Date:7/25/2014)... July 25, 2014 Progress in understanding ... a new era of promising brain tumor treatments, according ... School, director of the Center for Neuro-Oncology, Dana-Farber Cancer ... annual Patient and Family Conference in Chicago, July 25-26, ... and new technology are impacting the development of new ...
Breaking Medicine News(10 mins):Health News:Manipulating key protein in the brain holds potential against obesity and diabetes 2Health News:Innerspire, LLC Continues National Expansion 2Health News:Innerspire, LLC Continues National Expansion 3Health News:Innerspire, LLC Continues National Expansion 4Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3Health News:American Brain Tumor Association Board of Directors Member Shares Story of Brain Tumor Survivorship 2Health News:American Brain Tumor Association Board of Directors Member Shares Story of Brain Tumor Survivorship 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 2Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 4
... a small amount of chocolate had lower risks of heart ... Failure , a journal of the American Heart Association. The ... looked at the relationship of the amount of high-quality chocolate ... The quality of chocolate consumed by the women had a ...
... they detect and treat drug-resistant staph infections, but most ... University of Illinois at Chicago. Researchers sent a ... in the U.S. to learn of their policies and ... All of the hospitals are members of Broadlane, a ...
... cells that are vital for airway repair in the lung ... are associated with a poor prognosis in patients who develop ... Jonsson Comprehensive Cancer Center have found. These adult stem ... are found in pre-cancerous areas, suggesting that these cells may ...
... has examined how a specialized Iyengar yoga program for women ... treatment, makes a difference in their recovery. For two ... a questionnaire about their physical and mental health at the ... at the end. After analyzing the data that was collected ...
... University Massey Cancer Center researchers have uncovered a new ... not always cause inflammation, chronic inflammation is known to ... published in the June issue of Nature , ... Ph.D., and their co-authors examine how sphingosine-1-phosphate (S1P), a ...
... , MONDAY, Aug. 16 (HealthDay News) -- The ... poses a health threat to clean-up workers, fishermen and members ... have examined the area. "Clinicians should be aware of, ... and related chemicals. Symptomatic patients should be asked about occupation ...
Cached Medicine News:Health News:Moderate chocolate consumption linked to lower risks of heart failure 2Health News:Moderate chocolate consumption linked to lower risks of heart failure 3Health News:MRSA policies differ among hospitals, study shows 2Health News:Lung stem cells vital to lung repair associated with poor cancer prognosis when found in tumor 2Health News:VCU Massey research finds new link between inflammation and cancer 2Health News:Gulf Oil Spill Still a Health Threat to Many, Researchers Report 2Health News:Gulf Oil Spill Still a Health Threat to Many, Researchers Report 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: